Analysts’ Viewpoint
The escalating global occurrence of chronic illnesses such as cardiovascular ailments, cancers, diabetes, and neurological disorders has intensified the need for timely disease detection, precise diagnostics, and tailored treatment methods, which is bolstering the biomarkers market growth.
Furthermore, the advent of personalized medicine and precision diagnostics has highlighted the importance of biomarkers in categorizing patients, selecting treatments, and monitoring therapeutic progress.
Technological advancements and the launch of more precise and effective diagnostic assays also play a key role in market expansion.
Additionally, supportive regulatory frameworks, surge in investments in healthcare research and development, and collaborations among academic institutions, pharmaceutical firms, and diagnostic companies have spurred innovation in biomarker identification and application, which is expected to offer lucrative biomarkers market opportunities during the forecast period.
The biomarkers market covers a broad range of measurable signals, such as genetic variances, protein levels, and biochemical alterations, which indicate biological functions, disease conditions, or responses to therapies. Biomarkers have a critical role across various sectors, including diagnostics, drug exploration, personalized medicine, and clinical studies.
Significant progress in technology has notably reshaped the biomarkers arena, resulting in the introduction of more precise, sensitive, and high-capacity assays.
Next-generation sequencing (NGS), polymerase chain reaction (PCR), immunoassays, mass spectrometry, and other advanced methods facilitate the identification and measurement of biomarkers with unparalleled accuracy and efficacy.
These advancements have transformed disease detection, patient categorization, treatment choice, and therapeutic monitoring, thus fueling market progress.
| Attribute | Detail |
|---|---|
| Drivers |
|
Biomarkers, which are measurable signs in the body, play a key role in detecting chronic diseases and conditions such as heart disease, cancer, diabetes, and neurological disorders early and monitoring how they progress.
They give important information about a person's health, how the disease is progressing, and how well they respond to treatment, which is crucial for personalized healthcare.
According to the World Health Organization, non-communicable diseases (NCDs) cause 74% of all deaths worldwide, with cardiovascular diseases being the leading cause, followed by cancer, chronic respiratory diseases, and diabetes.
In the United States, 60% of people have at least one chronic condition, such as heart disease or diabetes, which are the main causes of death and disability.
In India, 21% of older adults have at least one chronic disease, with high rates in rural areas compared to urban ones. Hypertension and diabetes are the most common chronic diseases in India, especially in Kerala, Andhra Pradesh, West Bengal, and Goa.
By helping detect diseases early, improving diagnosis accuracy, and supporting personalized medicine, biomarkers play a crucial role in tackling the increasing burden of chronic diseases worldwide.
The rise of companion diagnostics in the biomarkers market is changing the approach toward personalized medicine. These tools help doctors match treatments with specific biomarkers in patients, making treatments more targeted and effective. Companion diagnostics look at genetic differences or protein levels in patients to create personalized treatment plans.
They give doctors the information they need to choose the best treatment for each patient. People are being afflicted with complex conditions such as cancer that need better treatment options.
Companion diagnostics help doctors figure out which patients will respond best to certain treatments, which can reduce side effects and make treatments work better.
In personalized medicine, companion diagnostics help separate patients into groups based on how they respond to drugs. This helps doctors understand which treatments work best for different groups of patients.
This separation is based on how the treatment works and is studied through research or clinical trials, making medical treatments more precise and effective. Thus the importance of biomarkers in companion diagnostics is a major market catalyst.
In terms of product & service, the global biomarkers market segmentation includes consumables, equipment, and services. The consumables segment is expected to dominate during the forecast period.
Biomarker assays typically require consumables such as reagents, kits, and other laboratory supplies for sample preparation, analysis, and detection.
These consumables are essential to conduct research and diagnostics related to biomarkers, which serve as vital indicators of biological processes, disease states, or responses to therapies.
Ongoing research in personalized medicine, oncology, neurology, and cardiovascular diseases is spurring the demand for consumables in the biomarkers market. Furthermore, the surge in prevalence of chronic diseases and the growth in emphasis on early disease detection and prevention are boosting market dynamics.
Based on application, the market is classified into diagnostics, drug discovery & development, personalized medicine, disease risk assessment, and others.
As per the biomarkers industry report, the diagnostics segment commands a substantial market share and is experiencing rapid growth. Biomarkers act as measurable signals of biological functions, disease conditions, or responses to treatments, providing crucial insights for diagnostic applications.
As chronic diseases become more prevalent and personalized medicine gains prominence, the need for biomarker-based diagnostics is increasing. These tools empower healthcare providers to detect diseases early, track their advancement, and customize treatment plans for each patient.
Furthermore, ongoing technological advancements have led to the launch of more precise and effective diagnostic tests, encouraging the widespread adoption of biomarker-based diagnostics across diverse medical fields.
In terms of disease indication, the biomarkers market has been divided into cancer, neurological disorders, cardiovascular disorders, infectious diseases, immune disorders, and others.
As per biomarkers market trends, the cancer disease indication segment is anticipated to lead in the next few years. Cancer remains a significant cause of mortality worldwide, with nearly 10 million deaths reported in 2020, representing approximately one-sixth of all fatalities, as per the World Health Organization.
Common cancer types include lung, breast, colon, rectal, and prostate cancers. Lifestyle factors such as tobacco use, obesity, excessive alcohol consumption, poor diet, and sedentary behavior contribute to around one-third of cancer-related deaths. Surge in incidence of cancer, particularly lung cancer globally, serves as a significant driver for this segment.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
North America is expected to emerge as a highly profitable market during the forecast period. The region's substantial disease burden, widespread acceptance of biomarkers for diagnostic, drug development, and prognostic applications, and a notable increase in research funding are boosting the North America biomarkers market share.
The region is further likely to benefit from an upsurge in product launches and high demand for biomarkers, contributing positively to the regional market's growth trajectory.
Europe is seeing an increase in focus on personalized medicine and precise diagnostics, which depend extensively on biomarkers for categorizing patients, selecting treatments, and monitoring therapeutic outcomes.
Additionally, favorable regulatory environments and rise in investments in healthcare research and development are driving market development in the region.
Asia Pacific is grappling with a mounting burden of cancer, with projections indicating a substantial rise in new cases by 2030 compared to 2020. To access more tailored and effective treatments, an increasing number of patients are undergoing biomarker testing.
With the escalating incidence of cancer, molecular testing technologies such as next-generation sequencing (NGS) and PCR-based molecular diagnostics (MDx) are gaining considerable importance in the region.
The global biomarkers market is fragmented with the presence of several players. Abbott Laboratories, Agilent Technology, Becton, Dickinson and Company, Bio-Rad Laboratories, BioMerieux SA (Astute Medical), Merck KGaA, Qiagen NV, Quanterix, Quest Diagnostics, and Thermo Fisher Scientific Inc. are the major biomarkers market manufacturers.
Each of these companies have been profiled in the biomarkers market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail | |
|---|---|---|
| Market Size in 2022 | US$ 51.2 Bn | |
| Forecast Value in 2031 | More than US$ 125.6 Bn | |
| Growth Rate (CAGR) | 10.4% | |
| Forecast Period | 2023-2031 | |
| Historical Data Available for | 2017-2021 | |
| Quantitative Units | US$ Bn for Value | |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. | |
| Competition Landscape |
|
|
| Format | Electronic (PDF) + Excel | |
| Segmentation |
|
|
| Regions Covered |
|
|
| Countries Covered |
|
|
| Companies Profiled |
|
|
| Customization Scope | Available upon request | |
| Pricing | Available upon request | |
It was valued at US$ 51.2 Bn in 2022
It is projected to reach more than US$ 125.6 Bn by the end of 2031
The CAGR is anticipated to be 10.4% from 2023 to 2031
North America is expected to account for largest share from 2023 to 2031
Abbott Laboratories, Agilent Technology, Becton, Dickinson and Company, Bio-Rad Laboratories, BioMerieux SA (Astute Medical), Merck KGaA, Qiagen NV, Quanterix, Quest Diagnostics, and Thermo Fisher Scientific Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Biomarkers Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Biomarkers Market Analysis and Forecasts, 2017–2031
5. Key Insights
5.1. Technological Advancements
5.2. Disease Prevalence & Incidence Rate Globally with Key Countries
5.3. Regulatory Scenario by Region/globally
5.4. COVID-19 Impact Analysis
6. Global Biomarkers Market Analysis and Forecasts, By Product & Service
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Product & Service, 2017–2031
6.3.1. Consumables
6.3.2. Services
6.3.3. Equipment
6.4. Market Attractiveness By Product & Service
7. Global Biomarkers Market Analysis and Forecasts, By Disease Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Application, 2017–2031
7.3.1. Diagnostics
7.3.2. Drug Discovery & Development
7.3.3. Personalized Medicine
7.3.4. Disease Risk Assessment
7.3.5. Others
7.4. Market Attractiveness By Application
8. Global Biomarkers Market Analysis and Forecasts, By Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Type, 2017–2031
8.3.1. Safety Biomarkers
8.3.2. Susceptibility/Risk Biomarkers
8.3.3. Diagnostic Biomarkers
8.3.4. Prognostic Biomarkers
8.3.5. Monitoring Biomarkers
8.3.6. Predictive Biomarkers
8.3.7. Pharmacodynamic/Response Biomarkers
8.4. Market Attractiveness By Type
9. Global Biomarkers Market Analysis and Forecasts, By Disease Indication
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Disease Indication, 2017–2031
9.3.1. Cancer
9.3.2. Neurological Disorders
9.3.3. Cardiovascular Disorders
9.3.4. Infectious Diseases
9.3.5. Immune Disorders
9.3.6. Others
9.4. Market Attractiveness By Disease Indication
10. Global Biomarkers Market Analysis and Forecasts, By Region
10.1. Key Findings
10.2. Market Value Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Region
11. North America Biomarkers Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Product & Service, 2017–2031
11.2.1. Consumables
11.2.2. Services
11.2.3. Equipment
11.3. Market Value Forecast By Application, 2017–2031
11.3.1. Diagnostics
11.3.2. Drug Discovery & Development
11.3.3. Personalized Medicine
11.3.4. Disease Risk Assessment
11.3.5. Others
11.4. Market Value Forecast By Type, 2017–2031
11.4.1. Safety Biomarkers
11.4.2. Susceptibility/Risk Biomarkers
11.4.3. Diagnostic Biomarkers
11.4.4. Prognostic Biomarkers
11.4.5. Monitoring Biomarkers
11.4.6. Predictive Biomarkers
11.4.7. Pharmacodynamic/Response Biomarkers
11.5. Market Value Forecast By Disease Indication, 2017–2031
11.5.1. Cancer
11.5.2. Neurological Disorders
11.5.3. Cardiovascular Disorders
11.5.4. Infectious Diseases
11.5.5. Immune Disorders
11.5.6. Others
11.6. Market Value Forecast By Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Product & Service
11.7.2. By Application
11.7.3. By Type
11.7.4. By Disease Indication
11.7.5. By Country
12. Europe Biomarkers Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Product & Service, 2017–2031
12.2.1. Consumables
12.2.2. Services
12.2.3. Equipment
12.3. Market Value Forecast By Application, 2017–2031
12.3.1. Diagnostics
12.3.2. Drug Discovery & Development
12.3.3. Personalized Medicine
12.3.4. Disease Risk Assessment
12.3.5. Others
12.4. Market Value Forecast By Type, 2017–2031
12.4.1. Safety Biomarkers
12.4.2. Susceptibility/Risk Biomarkers
12.4.3. Diagnostic Biomarkers
12.4.4. Prognostic Biomarkers
12.4.5. Monitoring Biomarkers
12.4.6. Predictive Biomarkers
12.4.7. Pharmacodynamic/Response Biomarkers
12.5. Market Value Forecast By Disease Indication, 2017–2031
12.5.1. Cancer
12.5.2. Neurological Disorders
12.5.3. Cardiovascular Disorders
12.5.4. Infectious Diseases
12.5.5. Immune Disorders
12.5.6. Others
12.6. Market Value Forecast By Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Product & Service
12.7.2. By Application
12.7.3. By Type
12.7.4. By Disease Indication
12.7.5. By Country/Sub-region
13. Asia Pacific Biomarkers Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Product & Service, 2017–2031
13.2.1. Consumables
13.2.2. Services
13.2.3. Equipment
13.3. Market Value Forecast By Application, 2017–2031
13.3.1. Diagnostics
13.3.2. Drug Discovery & Development
13.3.3. Personalized Medicine
13.3.4. Disease Risk Assessment
13.3.5. Others
13.4. Market Value Forecast By Type, 2017–2031
13.4.1. Safety Biomarkers
13.4.2. Susceptibility/Risk Biomarkers
13.4.3. Diagnostic Biomarkers
13.4.4. Prognostic Biomarkers
13.4.5. Monitoring Biomarkers
13.4.6. Predictive Biomarkers
13.4.7. Pharmacodynamic/Response Biomarkers
13.5. Market Value Forecast By Disease Indication, 2017–2031
13.5.1. Cancer
13.5.2. Neurological Disorders
13.5.3. Cardiovascular Disorders
13.5.4. Infectious Diseases
13.5.5. Immune Disorders
13.5.6. Others
13.6. Market Value Forecast By Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Product & Service
13.7.2. By Application
13.7.3. By Type
13.7.4. By Disease Indication
13.7.5. By Country/Sub-region
14. Latin America Biomarkers Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Product & Service, 2017–2031
14.2.1. Consumables
14.2.2. Services
14.2.3. Equipment
14.3. Market Value Forecast By Application, 2017–2031
14.3.1. Diagnostics
14.3.2. Drug Discovery & Development
14.3.3. Personalized Medicine
14.3.4. Disease Risk Assessment
14.3.5. Others
14.4. Market Value Forecast By Type, 2017–2031
14.4.1. Safety Biomarkers
14.4.2. Susceptibility/Risk Biomarkers
14.4.3. Diagnostic Biomarkers
14.4.4. Prognostic Biomarkers
14.4.5. Monitoring Biomarkers
14.4.6. Predictive Biomarkers
14.4.7. Pharmacodynamic/Response Biomarkers
14.5. Market Value Forecast By Disease Indication, 2017–2031
14.5.1. Cancer
14.5.2. Neurological Disorders
14.5.3. Cardiovascular Disorders
14.5.4. Infectious Diseases
14.5.5. Immune Disorders
14.5.6. Others
14.6. Market Value Forecast By Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Product & Service
14.7.2. By Application
14.7.3. By Type
14.7.4. By Disease Indication
14.7.5. By Country/Sub-region
15. Middle East & Africa Biomarkers Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Product & Service, 2017–2031
15.2.1. Consumables
15.2.2. Services
15.2.3. Equipment
15.3. Market Value Forecast By Application, 2017–2031
15.3.1. Diagnostics
15.3.2. Drug Discovery & Development
15.3.3. Personalized Medicine
15.3.4. Disease Risk Assessment
15.3.5. Others
15.4. Market Value Forecast By Type, 2017–2031
15.4.1. Safety Biomarkers
15.4.2. Susceptibility/Risk Biomarkers
15.4.3. Diagnostic Biomarkers
15.4.4. Prognostic Biomarkers
15.4.5. Monitoring Biomarkers
15.4.6. Predictive Biomarkers
15.4.7. Pharmacodynamic/Response Biomarkers
15.5. Market Value Forecast By Disease Indication, 2017–2031
15.5.1. Cancer
15.5.2. Neurological Disorders
15.5.3. Cardiovascular Disorders
15.5.4. Infectious Diseases
15.5.5. Immune Disorders
15.5.6. Others
15.6. Market Value Forecast By Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Product & Service
15.7.2. By Application
15.7.3. By Type
15.7.4. By Disease Indication
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Share Analysis By Company (2022)
16.2. Company Profiles
16.2.1. Abbott Laboratories
16.2.1.1. Company Overview
16.2.1.2. Financial Overview
16.2.1.3. Product Portfolio
16.2.1.4. Business Strategies
16.2.1.5. Recent Developments
16.2.2. Agilent Technology
16.2.2.1. Company Overview
16.2.2.2. Financial Overview
16.2.2.3. Product Portfolio
16.2.2.4. Business Strategies
16.2.2.5. Recent Developments
16.2.3. Becton, Dickinson and Company
16.2.3.1. Company Overview
16.2.3.2. Financial Overview
16.2.3.3. Product Portfolio
16.2.3.4. Business Strategies
16.2.3.5. Recent Developments
16.2.4. Bio-Rad Laboratories
16.2.4.1. Company Overview
16.2.4.2. Financial Overview
16.2.4.3. Product Portfolio
16.2.4.4. Business Strategies
16.2.4.5. Recent Developments
16.2.5. BioMerieux SA (Astute Medical)
16.2.5.1. Company Overview
16.2.5.2. Financial Overview
16.2.5.3. Product Portfolio
16.2.5.4. Business Strategies
16.2.5.5. Recent Developments
16.2.6. Merck KGaA
16.2.6.1. Company Overview
16.2.6.2. Financial Overview
16.2.6.3. Product Portfolio
16.2.6.4. Business Strategies
16.2.6.5. Recent Developments
16.2.7. Qiagen NV
16.2.7.1. Company Overview
16.2.7.2. Financial Overview
16.2.7.3. Product Portfolio
16.2.7.4. Business Strategies
16.2.7.5. Recent Developments
16.2.8. Quanterix
16.2.8.1. Company Overview
16.2.8.2. Financial Overview
16.2.8.3. Product Portfolio
16.2.8.4. Business Strategies
16.2.8.5. Recent Developments
16.2.9. Quest Diagnostics
16.2.9.1. Company Overview
16.2.9.2. Financial Overview
16.2.9.3. Product Portfolio
16.2.9.4. Business Strategies
16.2.9.5. Recent Developments
16.2.10. Thermo Fisher Scientific Inc.
16.2.10.1. Company Overview
16.2.10.2. Financial Overview
16.2.10.3. Product Portfolio
16.2.10.4. Business Strategies
16.2.10.5. Recent Developments
List of Tables
Table 01: Global Biomarkers Market Value (US$ Mn) Forecast, by Product & Service, 2017–2031
Table 02: Global Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 03: Global Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 04: Global Biomarkers Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 05: Global Biomarkers Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Biomarkers Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: North America Biomarkers Market Value (US$ Mn) Forecast, by Product & Service, 2017–2031
Table 08: North America Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 09: North America Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 10: North America Biomarkers Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 11: Europe Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 12: Europe Biomarkers Market Value (US$ Mn) Forecast, by Product & Service, 2017–2031
Table 13: Europe Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 14: Europe Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 15: Europe Biomarkers Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 16: Asia Pacific Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Asia Pacific Biomarkers Market Value (US$ Mn) Forecast, by Product & Service, 2017–2031
Table 18: Asia Pacific Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 19: Asia Pacific Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 20: Asia Pacific Biomarkers Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 21: Latin America Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Latin America Biomarkers Market Value (US$ Mn) Forecast, by Product & Service, 2017–2031
Table 23: Latin America Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 24: Latin America Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 25: Latin America Biomarkers Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 26: Middle East & Africa Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 27: Middle East & Africa Biomarkers Market Value (US$ Mn) Forecast, by Product & Service, 2017–2031
Table 28: Middle East & Africa Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 29: Middle East & Africa Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 30: Middle East & Africa Biomarkers Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031
List of Figures
Figure 01: Global Biomarkers Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Biomarkers Market Value Share, by Product & Service, 2022
Figure 03: Global Biomarkers Market Value Share, by Application, 2022
Figure 04: Global Biomarkers Market Value Share, by Type, 2022
Figure 05: Global Biomarkers Market Value Share, by Disease Indication, 2022
Figure 06: Global Biomarkers Market Value Share, by Region, 2022
Figure 07: Global Biomarkers Market Value (US$ Mn) Share Analysis, by Product & Service, 2022–2031
Figure 08: Global Biomarkers Market Share Analysis, by Product & Service, 2022
Figure 09: Global Biomarkers Market Share Analysis, by Product & Service, 2031
Figure 10: Global Biomarkers Market Attractiveness Analysis, by Product & Service, 2023–2031
Figure 11: Global Biomarkers Market Value (US$ Mn), by Consumables, 2017–2031
Figure 12: Global Biomarkers Market Value Share Analysis, by Consumables, 2022–2031
Figure 13: Global Biomarkers Market Value (US$ Mn), by Services, 2017–2031
Figure 14: Global Biomarkers Market Value Share Analysis, by Services, 2022–2031
Figure 15: Global Biomarkers Market Value (US$ Mn), by Equipment, 2017–2031
Figure 16: Global Biomarkers Market Value Share Analysis, by Equipment, 2022–2031
Figure 17: Global Biomarkers Market Value (US$ Mn) Share Analysis, by Application, 2022–2031
Figure 18: Global Biomarkers Market Share Analysis, by Application, 2022
Figure 19: Global Biomarkers Market Share Analysis, by Application, 2031
Figure 20: Global Biomarkers Market Attractiveness Analysis, by Application, 2023–2031
Figure 21: Global Biomarkers Market Value (US$ Mn), by Diagnostics, 2017–2031
Figure 22: Global Biomarkers Market Value Share Analysis, by Diagnostics, 2022–2031
Figure 23: Global Biomarkers Market Value (US$ Mn), by Drug Discovery & Development, 2017–2031
Figure 24: Global Biomarkers Market Value Share Analysis, by Drug Discovery & Development, 2022–2031
Figure 25: Global Biomarkers Market Value (US$ Mn), by Personalized Medicine, 2017–2031
Figure 26: Global Biomarkers Market Value Share Analysis, by Personalized Medicine, 2022–2031
Figure 27: Global Biomarkers Market Value (US$ Mn), by Disease Risk Assessment, 2017–2031
Figure 28: Global Biomarkers Market Value Share Analysis, by Disease Risk Assessment, 2022–2031
Figure 29: Global Biomarkers Market Value (US$ Mn), by Others, 2017–2031
Figure 30: Global Biomarkers Market Value Share Analysis, by Others, 2022–2031
Figure 31: Global Biomarkers Market Value (US$ Mn) Share Analysis, by Type, 2022–2031
Figure 32: Global Biomarkers Market Share Analysis, by Type, 2022
Figure 33: Global Biomarkers Market Share Analysis, by Type, 2031
Figure 34: Global Biomarkers Market Attractiveness Analysis, by Type, 2023–2031
Figure 35: Global Biomarkers Market Value (US$ Mn), by Safety Biomarkers, 2017–2031
Figure 36: Global Biomarkers Market Value Share Analysis, by Safety Biomarkers, 2022–2031
Figure 37: Global Biomarkers Market Value (US$ Mn), by Susceptibility/Risk Biomarkers, 2017–2031
Figure 38: Global Biomarkers Market Value Share Analysis, by Susceptibility/Risk Biomarkers, 2022–2031
Figure 39: Global Biomarkers Market Value (US$ Mn), by Diagnostic Biomarkers, 2017–2031
Figure 40: Global Biomarkers Market Value Share Analysis, by Diagnostic Biomarkers, 2022–2031
Figure 41: Global Biomarkers Market Value (US$ Mn), by Prognostic Biomarkers, 2017–2031
Figure 42: Global Biomarkers Market Value Share Analysis, by Prognostic Biomarkers, 2022–2031
Figure 43: Global Biomarkers Market Value (US$ Mn), by Monitoring Biomarkers, 2017–2031
Figure 44: Global Biomarkers Market Value Share Analysis, by Monitoring Biomarkers, 2022–2031
Figure 45: Global Biomarkers Market Value (US$ Mn), by Predictive Biomarkers, 2017–2031
Figure 46: Global Biomarkers Market Value Share Analysis, by Predictive Biomarkers, 2022–2031
Figure 47: Global Biomarkers Market Value (US$ Mn), by Pharmacodynamic/Response Biomarkers, 2017–2031
Figure 48: Global Biomarkers Market Value Share Analysis, by Pharmacodynamic/Response Biomarkers, 2022–2031
Figure 49: Global Biomarkers Market Value (US$ Mn) Share Analysis, by Disease Indication, 2022–2031
Figure 50: Global Biomarkers Market Share Analysis, by Disease Indication, 2022
Figure 51: Global Biomarkers Market Share Analysis, by Disease Indication, 2031
Figure 52: Global Biomarkers Market Attractiveness Analysis, by Disease Indication, 2023–2031
Figure 53: Global Biomarkers Market Value (US$ Mn), by Cancer, 2017–2031
Figure 54: Global Biomarkers Market Value Share Analysis, by Cancer, 2022–2031
Figure 55: Global Biomarkers Market Value (US$ Mn), by Neurological Disorders, 2017–2031
Figure 56: Global Biomarkers Market Value Share Analysis, by Neurological Disorders, 2022–2031
Figure 57: Global Biomarkers Market Value (US$ Mn), by Cardiovascular Disorders, 2017–2031
Figure 58: Global Biomarkers Market Value Share Analysis, by Cardiovascular Disorders, 2022–2031
Figure 59: Global Biomarkers Market Value (US$ Mn), by Infectious Diseases, 2017–2031
Figure 60: Global Biomarkers Market Value Share Analysis, by Infectious Diseases, 2022–2031
Figure 61: Global Biomarkers Market Value (US$ Mn), by Immune Disorders, 2017–2031
Figure 62: Global Biomarkers Market Value Share Analysis, by Immune Disorders, 2022–2031
Figure 63: Global Biomarkers Market Value (US$ Mn), by Others, 2017–2031
Figure 64: Global Biomarkers Market Value Share Analysis, by Others, 2022–2031
Figure 65: Global Biomarkers Market Value Share Analysis, by Region, 2022–2031
Figure 66: Global Biomarkers Market Share Analysis, by Region, 2022
Figure 67: Global Biomarkers Market Share Analysis, by Region, 2031
Figure 68: Global Biomarkers Market Attractiveness Analysis, by Region, 2023–2031
Figure 69: North America Biomarkers Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 70: North America Biomarkers Market Value Share Analysis, by Country, 2022–2031
Figure 71: North America Biomarkers Market Attractiveness Analysis, by Country, 2023–2031
Figure 72: North America Biomarkers Market Value (US$ Mn) Share Analysis, by Product & Service, 2022–2031
Figure 73: North America Biomarkers Market Attractiveness Analysis, by Product & Service, 2023–2031
Figure 74: North America Biomarkers Market Value (US$ Mn) Share Analysis, by Application, 2022–2031
Figure 75: North America Biomarkers Market Attractiveness Analysis, by Application, 2023–2031
Figure 76: North America Biomarkers Market Value (US$ Mn) Share Analysis, by Type, 2022–2031
Figure 77: North America Biomarkers Market Attractiveness Analysis, by Type, 2023–2031
Figure 78: North America Biomarkers Market Value (US$ Mn) Share Analysis, by Type, 2022–2031
Figure 79: North America Biomarkers Market Attractiveness Analysis, by Type, 2023–2031
Figure 80: Europe Biomarkers Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 81: Europe Biomarkers Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 82: Europe Biomarkers Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 83: Europe Biomarkers Market Value (US$ Mn) Share Analysis, by Product & Service, 2022–2031
Figure 84: Europe Biomarkers Market Attractiveness Analysis, by Product & Service, 2023–2031
Figure 85: Europe Biomarkers Market Value (US$ Mn) Share Analysis, by Application, 2022–2031
Figure 86: Europe Biomarkers Market Attractiveness Analysis, by Application, 2023–2031
Figure 87: Europe Biomarkers Market Value (US$ Mn) Share Analysis, by Type, 2022–2031
Figure 88: Europe Biomarkers Market Attractiveness Analysis, by Type, 2023–2031
Figure 89: Europe Biomarkers Market Value (US$ Mn) Share Analysis, by Type, 2022–2031
Figure 90: Europe Biomarkers Market Attractiveness Analysis, by Type, 2023–2031
Figure 91: Asia Pacific Biomarkers Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 92: Asia Pacific Biomarkers Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 93: Asia Pacific Biomarkers Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 94: Asia Pacific Biomarkers Market Value (US$ Mn) Share Analysis, by Product & Service, 2022–2031
Figure 95: Asia Pacific Biomarkers Market Attractiveness Analysis, by Product & Service, 2023–2031
Figure 96: Asia Pacific Biomarkers Market Value (US$ Mn) Share Analysis, by Application, 2022–2031
Figure 97: Asia Pacific Biomarkers Market Attractiveness Analysis, by Application, 2023–2031
Figure 98: Asia Pacific Biomarkers Market Value (US$ Mn) Share Analysis, by Type, 2022–2031
Figure 99: Asia Pacific Biomarkers Market Attractiveness Analysis, by Type, 2023–2031
Figure 100: Asia Pacific Biomarkers Market Value (US$ Mn) Share Analysis, by Type, 2022–2031
Figure 101: Asia Pacific Biomarkers Market Attractiveness Analysis, by Type, 2023–2031
Figure 102: Latin America Biomarkers Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 103: Latin America Biomarkers Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 104: Latin America Biomarkers Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 105: Latin America Biomarkers Market Value (US$ Mn) Share Analysis, by Product & Service, 2022–2031
Figure 106: Latin America Biomarkers Market Attractiveness Analysis, by Product & Service, 2023–2031
Figure 107: Latin America Biomarkers Market Value (US$ Mn) Share Analysis, by Application, 2022–2031
Figure 108: Latin America Biomarkers Market Attractiveness Analysis, by Application, 2023–2031
Figure 109: Latin America Biomarkers Market Value (US$ Mn) Share Analysis, by Type, 2022–2031
Figure 110: Latin America Biomarkers Market Attractiveness Analysis, by Type, 2023–2031
Figure 111: Latin America Biomarkers Market Value (US$ Mn) Share Analysis, by Type, 2022–2031
Figure 112: Latin America Biomarkers Market Attractiveness Analysis, by Type, 2023–2031
Figure 113: Middle East & Africa Biomarkers Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 114: Middle East & Africa Biomarkers Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 115: Middle East & Africa Biomarkers Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 116: Middle East & Africa Biomarkers Market Value (US$ Mn) Share Analysis, by Product & Service, 2022–2031
Figure 117: Middle East & Africa Biomarkers Market Attractiveness Analysis, by Product & Service, 2023–2031
Figure 118: Middle East & Africa Biomarkers Market Value (US$ Mn) Share Analysis, by Application, 2022–2031
Figure 119: Middle East & Africa Biomarkers Market Attractiveness Analysis, by Application, 2023–2031
Figure 120: Middle East & Africa Biomarkers Market Value (US$ Mn) Share Analysis, by Type, 2022–2031
Figure 121: Middle East & Africa Biomarkers Market Attractiveness Analysis, by Type, 2023–2031
Figure 122: Middle East & Africa Biomarkers Market Value (US$ Mn) Share Analysis, by Type, 2022–2031
Figure 123: Middle East & Africa Biomarkers Market Attractiveness Analysis, by Type, 2023–2031
Figure 124: Biomarkers Market: Company Share Analysis, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Biomarkers Market
